Search

Your search keyword '"Kyaw, Moe H"' showing total 5 results
Start Over Author "Kyaw, Moe H" Journal clinical infectious diseases
5 results on '"Kyaw, Moe H"'

3. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003

Author

Greene, Carolyn M., Kyaw, Moe H., Ray, Susan M., Schaffner, William, Lynfield, Ruth, Barrett, Nancy L., Long, Christine, Gershman, Ken, Pilishvili, Tamar, Roberson, Angela, Zell, Ellizabeth R., Whitney, Cynthia G., and Bennett, Nancy M.

Subjects
Pneumococcal infections -- Prevention, Polysaccharides -- Research, Pneumococcal vaccine -- Research, Health, Health care industry
Published
2006

4. Invasive pneumococcal disease in Scotland, 1999-2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy

Author

Kyaw, Moe H., Christie, Peter, Clarke, Stuart C., Mooney, John D., Ahmed, Syed, Jones, Ian G., and Campbell, Harry

Subjects
Statistics, Epidemics -- Management, Epidemiology -- Research, Pneumococcal infections -- Demographic aspects, Pneumococcal vaccine -- Usage, Epidemics -- Scotland, Epidemics -- United States, Company business management, Health, Health care industry
Published
2003

5. Bordetella Pertussis Infections in Vaccinated and Unvaccinated Adolescents and Adults, as Assessed in a National Prospective Randomized Acellular Pertussis Vaccine Trial (APERT).

Author

Greene, Carolyn M., Kyaw, Moe H., Ray, Susan M., Schaffner, William, Lynfield, Ruth, Barrett, Nancy L., Long, Christine, Gershman, Ken, Pilishvili, Tamar, Roberson, Angela, Zell, Elizabeth R., Whitney, Cynthia G., and Bennett, Nancy M.

Subjects
*BORDETELLA pertussis, *WHOOPING cough vaccines, *PREVENTIVE medicine, *BACTERIAL diseases, *MICROBIOLOGY
Abstract

Background. Acellular pertussis (aP) booster immunizations have been recommended for adolescents and older persons to enhance long-term protection and to possibly reduce community transmission of infections. Methods. This was a multicenter, randomized, double-blind vaccine trial in which one-half of the subjects received aP vaccine and one-half received hepatitis A vaccine (control subjects). All subjects were observed for almost 2 years for cough illnesses, and all underwent microbiologic and serologic studies for detection of pertussis infection. Immunoglobulin G (IgG) and immunoglobulin A (IgA) antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae 2/3 were measured by enzyme-linked immunosorbent assay in serum samples obtained 1 and 12 months after immunization. Infection rates were determined with a variety of serologic criteria for control and vaccinated subjects. The incidence of prolonged cough illness was ascertained for subjects with and subjects without serologic evidence of infection. Results. Infection rates among control subjects are particularly representative of those in nonimmunized adults. Among control subjects, 0.4%-2.7% had increases in pertussis antibody of various types and degrees over 1 year, and 20%-46% had prolonged cough illnesses during this interval. Pertussis toxin antibody had the greatest specificity for detecting increases in antibody levels. Asymptomatic infections were ~5 times more common than clinical illnesses that met a strict clinical and microbiologic case definition. Relative to control subjects, aP-immunized subjects may have fewer increases in the antibody level (i.e., infections), especially for antibodies to fimbriae 2/3 (an antigen not in the vaccine). Conclusions. Pertussis infections in older persons are largely asymptomatic. aP boosters confer protection for adolescents and adults against symptomatic pertussis and likely confer protection against mild and asymptomatic infections, and use of boosters may reduce transmission to others, especially infants. [ABSTRACT FROM AUTHOR]

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results